Please login to order a test.
c-KIT Mutation Analysis in Tumors of Hematopoietic Tissue
c-KIT is a proto-oncogene that encodes a type III transmembrane tyrosine kinase. c-KIT and its ligand stem cell factor have a key role in survival, proliferation, differentiation, and functional activation of hematopoietic progenitor cells. c-KIT mutations are reported in nearly all systemic mastocytosis, 20% to 40% core-binding factor (CBF) acute myeloid leukemia (AML), and approximately 20% high-grade myelodysplastic syndrome (MDS) and MDS-derived AML. c-KIT mutation in AML confers increased risk of relapse and decreased overall survival. Tyrosine kinase inhibitor, such as imatinib, has been evaluated to treat systemic mastocytosis and c-KIT-positive AML and MDS, and it was found effective as a single reagent or combination therapy.
Genomic DNA was purified from the provided specimen. Exons 8 and 17 of c-KIT gene coding were subjected to PCR amplification and bidirectional sequencing in duplicate to identify sequence variations. This assay has a sensitivity to detect approximately 10% population of cells containing the c-KIT mutations in a background of nonmutant cells. This assay will not detect the mutation below the sensitivity of the assay. Molecular-based testing is highly accurate but, as in any laboratory test, rare diagnostic errors may occur.
Polymerase chain reaction (PCR) and DNA sequencing
Whole blood or bone marrow
3 to 5 mL whole blood or 1 to 2 mL bone marrow
3 mL whole blood or 1 mL bone marrow
Submit at room temperature. Indicate date and time of collection on the test request form.
Causes for Rejection
Please direct any questions regarding this test to oncology customer service at 800-345-4363.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|480940||c-KIT Mutation, Liquid Tumor||480941||c-KIT Mutation Analysis Result||55201-8|
|480940||c-KIT Mutation, Liquid Tumor||480943||Nucleotide Change:||48004-6|
|480940||c-KIT Mutation, Liquid Tumor||480944||Amino Acid Change:||48005-3|
|480940||c-KIT Mutation, Liquid Tumor||480945||Background:||77202-0|
|480940||c-KIT Mutation, Liquid Tumor||480946||Methodology:||49549-9|
|480940||c-KIT Mutation, Liquid Tumor||480948||Reference:||N/A|
|480940||c-KIT Mutation, Liquid Tumor||480949||Director Review||72486-4|